The stock of Minerva Neurosciences Inc (NASDAQ:NERV) is a huge mover today! About 269,691 shares traded hands or 36.63% up from the average. Minerva Neurosciences Inc (NASDAQ:NERV) has risen 114.40% since April 27, 2016 and is uptrending. It has outperformed by 109.17% the S&P500.
The move comes after 5 months negative chart setup for the $444.04 million company. It was reported on Nov, 30 by Barchart.com. We have $12.12 PT which if reached, will make NASDAQ:NERV worth $26.64 million less.
Analysts await Minerva Neurosciences Inc (NASDAQ:NERV) to report earnings on March, 13. They expect $-0.23 EPS, up 32.35% or $0.11 from last year’s $-0.34 per share. After $-0.24 actual EPS reported by Minerva Neurosciences Inc for the previous quarter, Wall Street now forecasts -4.17% EPS growth.
Minerva Neurosciences Inc (NASDAQ:NERV) Ratings Coverage
Out of 2 analysts covering Minerva Neurosciences (NASDAQ:NERV), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Minerva Neurosciences has been the topic of 3 analyst reports since March 9, 2016 according to StockzIntelligence Inc. JMP Securities maintained Minerva Neurosciences Inc (NASDAQ:NERV) on Wednesday, March 9 with “Market Outperform” rating. The firm earned “Buy” rating on Friday, May 27 by Jefferies. The stock of Minerva Neurosciences Inc (NASDAQ:NERV) earned “Buy” rating by Jefferies on Thursday, May 12.
According to Zacks Investment Research, “Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company’s pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson’s disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States.”
More recent Minerva Neurosciences Inc (NASDAQ:NERV) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on June 27, 2014. Also Quotes.Wsj.com published the news titled: “News Minerva Neurosciences Inc.NERV” on June 20, 2014. Marketwatch.com‘s news article titled: “Minerva Neurosciences’ stock more than triples on heavy volume after drug …” with publication date: May 26, 2016 was also an interesting one.
NERV Company Profile
Minerva Neurosciences, Inc., incorporated on April 23, 2007, is a clinical-stage biopharmaceutical company. The Firm is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.